Why BofA worries about Hims & Hers. Hims & Hers stock has been a mega-outperformer for investors, growing more than 600% over ...
Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
Key Takeaways Shares of Hims & Hers Health touched a fresh record high in Wednesday trading after the company announced its ...
Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...
Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab ...
The Super Bowl aired a Hims & Hers commercial that is receiving backlash for its non-FDA approved weight loss drug. This drug ...
Hims & Hers is introducing at-home laboratory testing, expanding its platform to offer deeper health insights and more ...
Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results